AdaptHealth Earnings Call Transcripts
Fiscal Year 2026
-
Major operational streamlining and technology investments have driven record setup times and census growth across core segments. Exclusive capitated contracts with major payers like Kaiser and Humana are fueling expansion, while divestitures and M&A refine the portfolio. Regulatory changes and payer mix shifts continue to shape strategy.
-
The company is expanding its market share in sleep and respiratory care, leveraging technology and operational improvements to drive high adherence and patient satisfaction. Major contracts with Humana and Kaiser are fueling geographic growth, especially on the West Coast, while regulatory changes and industry consolidation present further opportunities.
Fiscal Year 2025
-
2025 saw record patient census, strong operational improvements, and the launch of the largest industry capitated contract, driving revenue and margin growth. Guidance for 2026 anticipates 6–8% revenue growth, margin expansion, and continued debt reduction, supported by technology and strategic acquisitions.
-
Capitated contracts are expanding, with a new $1B IDN deal and Humana renewal driving predictable revenue. Operational improvements and tech investments are boosting efficiency, while industry consolidation and steady reimbursement rates position the company for strong organic growth.
-
Q3 2025 delivered strong organic growth, record patient census in key segments, and improved profitability, driven by operational enhancements and new exclusive capitated contracts. Debt reduction and investments in technology and infrastructure position the company for accelerated growth in 2026.
-
Record growth in sleep apnea and operational improvements in diabetes are driving performance, while new large contracts and industry consolidation position the business for further margin expansion. Automation and AI investments are expected to yield significant cost savings, with free cash flow and debt reduction remaining top priorities.
-
Management restructuring and tech investments drove operational improvements and financial stability. A major five-year, $1 billion contract will expand reach and add new revenue streams, while diabetes and sleep segments show renewed growth.
-
Q2 2025 saw stable revenue and strong free cash flow, with a major five-year capitation contract set to drive future growth. Segment performance was mixed, but momentum is building, especially in sleep and diabetes health. Net leverage improved, and guidance for 2025 was reaffirmed.
-
Diabetes and sleep segments are showing operational improvements, with enhanced retention and new patient growth. Capitated business is expanding, industry consolidation is accelerating, and portfolio optimization is reducing debt and focusing on core segments.
-
Q1 2025 revenue and adjusted EBITDA exceeded guidance despite year-over-year declines, with strong respiratory and improving diabetes segments. Debt reduction and asset sales strengthened the balance sheet, and 2025 guidance was revised only for the incontinence asset sale, with tariff risks seen as manageable.
-
Revised summary: The business reorganized into four segments: sleep, respiratory, diabetes, and home wellness. Modest growth and flat margins are expected in 2025 due to investments in leadership and technology. Segment initiatives improve diabetes retention and sleep adherence, with strong interest in capitated contracts and limited tariff exposure.
-
Investments are focused on sleep, respiratory, and diabetes, with strong sleep market demand and operational improvements driving record adherence. Capitated contracts and disciplined M&A are key strategies, while 2025 free cash flow is guided at $200 million.
Fiscal Year 2024
-
Q4 and full year 2024 results exceeded guidance, with revenue and free cash flow growth despite headwinds from asset sales and reimbursement changes. Operational improvements and leadership changes are driving better performance, especially in Sleep and Diabetes Health, while 2025 is expected to be a transition year with stable margins and strong cash flow.
-
Integration and operational improvements are underway, with a new leadership team and a shift to four business segments. Sleep and respiratory segments are growing, while diabetes is in a turnaround phase with new strategies and leadership. Portfolio optimization and strong payer partnerships support a stable, optimistic outlook.
-
Management is focused on operational integration, segment clarity, and fixing internal issues, especially in the diabetes business. Sleep and respiratory segments are strong, while divestitures of non-core assets continue. Growth initiatives and further pharmacy expansion are planned for late 2025 and beyond.
-
Q3 2024 saw flat revenue as sleep and respiratory growth offset diabetes declines. Operational and leadership changes are underway in diabetes, with guidance lowered for the year. Debt reduction, tech investments, and a new segment structure position the company for future growth.
-
Leadership outlined a five-point action plan focused on organizational clarity, growth, and innovation. Q2 results exceeded expectations, with strong respiratory and sleep segments offsetting flat diabetes CGM sales. GLP-1 use among new CPAP patients is rising, with no negative impact on adherence observed.
-
Q2 2024 results met expectations with revenue up 1.6% and strong sleep segment growth. Diabetes revenue declined due to timing and payer shifts, but pharmacy channel expansion and new pump integrations are expected to drive a rebound in the second half. Net leverage improved and full-year guidance for revenue, EBITDA, and free cash flow was reaffirmed.